Novartis Surges As It Goes After Eli Lilly's Second Biggest MoneymakerInvestors Business Daily • 03/27/23
First Citizens shares leap on SVB deal as Novartis stock boosted by breast-cancer drug trialMarket Watch • 03/27/23
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancerGlobeNewsWire • 03/27/23
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onsetGlobeNewsWire • 03/19/23
After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)Zacks Investment Research • 03/01/23
Novartis announces the appointment of the Chairman-Designate of Sandoz Board of DirectorsGlobeNewsWire • 02/20/23
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®GlobeNewsWire • 02/03/23
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed ReportInvestors Business Daily • 02/01/23
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividendMarket Watch • 02/01/23